European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War) Total Liabilities

The latest total liabilities for EBACU is $8.5M as of December 2022. That compares with $7.6M in the prior-year period — up 12.3% year over year. Investors often review this figure alongside European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, EBACU's total liabilities moved from $7.6M to $8.5M — a 12.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in European Biotech Acquisition - Units (1 Ord Share Class A & 1/3 War)'s operating scale or balance-sheet position.

A total liabilities figure of $8.5M for EBACU is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EBACU's total liabilities ($8.5M), review year-over-year change from $7.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.